Literature DB >> 21481782

The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment.

Ning Li1, Sergei I Grivennikov, Michael Karin.   

Abstract

Tumor-associated inflammation is a consequence and a driver of tumorigenesis. Three papers in this issue of Cancer Cell demonstrate the importance of tumor-elicited inflammation in the development and progression of pancreatic ductal adenocarcinoma and esophageal squamous carcinoma. Disruption of tissue homeostasis culminates in activation of STAT3, generating a pro-tumorigenic inflammatory microenvironment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21481782      PMCID： PMC3111086          DOI： 10.1016/j.ccr.2011.03.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  11 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Authors:  Marina Lesina; Magdalena U Kurkowski; Katharina Ludes; Stefan Rose-John; Matthias Treiber; Günter Klöppel; Akihiko Yoshimura; Wolfgang Reindl; Bence Sipos; Shizuo Akira; Roland M Schmid; Hana Algül
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

3.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.

Authors:  Akihisa Fukuda; Sam C Wang; John P Morris; Alexandra E Folias; Angela Liou; Grace E Kim; Shizuo Akira; Kenneth M Boucher; Matthew A Firpo; Sean J Mulvihill; Matthias Hebrok
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

4.  Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene.

Authors:  Douglas B Stairs; Lauren J Bayne; Ben Rhoades; Maria E Vega; Todd J Waldron; Jiri Kalabis; Andres Klein-Szanto; Ju-Seog Lee; Jonathan P Katz; J Alan Diehl; Albert B Reynolds; Robert H Vonderheide; Anil K Rustgi
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

5.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Authors:  Wei Tan; Weizhou Zhang; Amy Strasner; Sergei Grivennikov; Jin Q Cheng; Robert M Hoffman; Michael Karin
Journal:  Nature       Date:  2011-02-16       Impact factor: 49.962

Review 6.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

7.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

8.  Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway.

Authors:  Eric T Sawey; Johnny A Johnson; Howard C Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

9.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.

Authors:  Carmen Guerra; Alberto J Schuhmacher; Marta Cañamero; Paul J Grippo; Lena Verdaguer; Lucía Pérez-Gallego; Pierre Dubus; Eric P Sandgren; Mariano Barbacid
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582
View more
  122 in total

1.  STAT3 can serve as a hit in the process of malignant transformation of primary cells.

Authors:  M Demaria; S Misale; C Giorgi; V Miano; A Camporeale; J Campisi; P Pinton; V Poli
Journal:  Cell Death Differ       Date:  2012-03-09       Impact factor: 15.828

Review 2.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 3.  Regulation of DNA glycosylases and their role in limiting disease.

Authors:  Harini Sampath; Amanda K McCullough; R Stephen Lloyd
Journal:  Free Radic Res       Date:  2012-02-06

Review 4.  Cancer and the microbiota.

Authors:  Wendy S Garrett
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

5.  HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.

Authors:  Ling Li; Wenhua Tang; Xiaoqing Wu; David Karnak; Xiaojie Meng; Rachel Thompson; Xinbao Hao; Yongmin Li; Xiaotan T Qiao; Jiayuh Lin; James Fuchs; Diane M Simeone; Zhi-Nan Chen; Theodore S Lawrence; Liang Xu
Journal:  Clin Cancer Res       Date:  2013-10-16       Impact factor: 12.531

6.  Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.

Authors:  Anne Schroeder; Andreas Herrmann; Gregory Cherryholmes; Claudia Kowolik; Ralf Buettner; Sumanta Pal; Hua Yu; Gerhard Müller-Newen; Richard Jove
Journal:  Cancer Res       Date:  2013-10-31       Impact factor: 12.701

7.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

8.  Transgenic expression of interferon-γ in mouse stomach leads to inflammation, metaplasia, and dysplasia.

Authors:  Li-Jyun Syu; Mohamad El-Zaatari; Kathryn A Eaton; Zhiping Liu; Manas Tetarbe; Theresa M Keeley; Joanna Pero; Jennifer Ferris; Dawn Wilbert; Ashley Kaatz; Xinlei Zheng; Xiotan Qiao; Marina Grachtchouk; Deborah L Gumucio; Juanita L Merchant; Linda C Samuelson; Andrzej A Dlugosz
Journal:  Am J Pathol       Date:  2012-10-01       Impact factor: 4.307

Review 9.  Cancer and inflammation.

Authors:  Lance L Munn
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-12-12

10.  Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Authors:  Beata Holkova; Maciej Kmieciak; Prithviraj Bose; Victor Y Yazbeck; Paul M Barr; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; April D Rollins; Erin M Cebula; Emily Pierce; Megan Herr; Heidi Sankala; Kevin T Hogan; Wen Wan; Changyong Feng; Derick R Peterson; Richard I Fisher; Steven Grant; Jonathan W Friedberg
Journal:  Leuk Lymphoma       Date:  2015-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.